Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436193 | 1.00 | MEN1 (0.47) | MEN1KMT2AMAPTUSP2MAPK1 | |
| SCHEMBL23495150 | 0.95 | HPGD (0.49) | MEN1KMT2AMAPTUSP2MAPK1 | |
| SCHEMBL29436242 | 0.95 | HPGD (0.49) | MEN1KMT2AMAPTUSP2MAPK1 | |
| SCHEMBL23495253 | 0.84 | LMNA (0.58) | MAPTUSP2MAPK1EPHX2ALDH1A1 | |
| SCHEMBL23495178 | 0.83 | MAPT (0.49) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL29436219 | 0.83 | MAPT (0.49) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL23495326 | 0.83 | MAPT (0.59) | MAPTUSP2MAPK1EPHX2ALDH1A1 | |
| SCHEMBL29436254 | 0.80 | MAPT (0.49) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL23495425 | 0.80 | MAPT (0.49) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL23495309 | 0.79 | MAPT (0.61) | KMT2AMAPTUSP2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248972-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4248972-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021231546-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885 |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MEN1 4467/4885KMT2A 3767/4885MAPT 1863/4885 |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885MAPT 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.